<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2095">
  <stage>Registered</stage>
  <submitdate>1/09/2008</submitdate>
  <approvaldate>1/09/2008</approvaldate>
  <nctid>NCT00745485</nctid>
  <trial_identification>
    <studytitle>Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid</studytitle>
    <scientifictitle>A Phase IV Study of the Safety and Feasibility of Rooms-based Infusion of Zoledronic Acid for Women With Post-menopausal Osteoporosis</scientifictitle>
    <utrn />
    <trialacronym>LISA</trialacronym>
    <secondaryid>CZOL446HAU27</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - zoledronic acid

Experimental: Zoldronic - 


Treatment: drugs: zoledronic acid


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bone Mineral Density</outcome>
      <timepoint>at baseline and month 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Bone turnover</outcome>
      <timepoint>at baseline and month 12</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Female after menopause with osteoporosis either: 70 years of age or older with a bone
        mineral density T-score of -3.0 or less OR with a fracture due to minimal trauma.</inclusivecriteria>
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Intravenous bisphosphonate within the past 12 months

          2. Abnormal levels of protein in the urine via dipstick at screening if not caused by
             bacterial infection

          3. Abnormal liver function tests greater than twice normal

          4. Evidence of high bone turnover

          5. Abnormal calcium blood levels

          6. Low Vitamin D levels

          7. Poor renal function

          8. Abnormal parathyroid function or uncontrolled, abnormal thyroid function

          9. History of eye inflammation

         10. History of diabetes leading to kidney or eye problems

         11. A history of cancer except some non-invasive cancers of skin, colon, breast and cervix

         12. Patients with severe dental problems or current dental infections Or requiring dental
             surgery

         13. Known sensitivity to zoledronic acid or bisphosphonates

        Other protocol defined inclusion/exclusion criteria may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>186</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Blacktown</hospital>
    <hospital>Novartis Investigative Site - Georgetown</hospital>
    <hospital>Novartis Investigative Site - Leichhardt</hospital>
    <hospital>Novartis Investigative Site - Manly</hospital>
    <hospital>Novartis Investigative Site - North Parramatta</hospital>
    <hospital>Novartis Investigative Site - Wentworthville</hospital>
    <hospital>Novartis Investigative Site - Caloundra</hospital>
    <hospital>Novartis Investigative Site - Southport</hospital>
    <hospital>Novartis Investigative Site - Ashford</hospital>
    <hospital>Novartis Investigative Site - Norwood</hospital>
    <hospital>Novartis Investigative Site - Footscray</hospital>
    <hospital>Novartis Investigative Site - Ringwood</hospital>
    <hospital>Novartis Investigative Site - Nedlands Perth</hospital>
    <hospital>Novartis Investigative Site - Nedlands</hospital>
    <postcode>2148 - Blacktown</postcode>
    <postcode>2298 - Georgetown</postcode>
    <postcode>2040 - Leichhardt</postcode>
    <postcode>2095 - Manly</postcode>
    <postcode>2150 - North Parramatta</postcode>
    <postcode>2150 - Wentworthville</postcode>
    <postcode>4551 - Caloundra</postcode>
    <postcode>4215 - Southport</postcode>
    <postcode>5035 - Ashford</postcode>
    <postcode>5067 - Norwood</postcode>
    <postcode>3011 - Footscray</postcode>
    <postcode>3134 - Ringwood</postcode>
    <postcode>6009 - Nedlands Perth</postcode>
    <postcode>WA 6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>1. The study will assess the safety and tolerability of a single-infusion of zoledronic
           acid 5 mg administered in a private medical practice setting by a nurse provided by a
           nationwide infusion service. Safety data will largely be monitored by investigating
           changes in the patients' well-being during the study.

        2. The study will pilot and test a Patient Registry and Infusion Service process, which
           will allow zoledronic acid to be administered to trial patients in the investigators'
           private rooms by a team of roving nurses.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00745485</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>